International lung cancer consortium: Pooled analysis of sequence variants in DNA repair and cell cycle pathways

Rayjean J. Hung, David C. Christiani, Angela Risch, Odilia Popanda, Aage Haugen, Shan Zienolddiny, Simone Benhamou, Christine Bouchardy, Qing Lan, Margaret R. Spitz, H. Erich Wichmann, Loic LeMarchand, Paolo Vineis, Giuseppe Matullo, Chikako Kiyohara, Zuo Feng Zhang, Benhnaz Pezeshki, Curtis Harris, Leah Mechanic, Adeline SeowDaniel P.K. Ng, Neonila Szeszenia-Dabrowska, David Zaridze, Jolanta Lissowska, Peter Rudnai, Eleonora Fabianova, Dana Mates, Lenka Foretova, Vladimir Janout, Vladimir Bencko, Neil Caporaso, Chu Chen, Eric J. Duell, Gary Goodman, John K. Field, Richard S. Houlston, Yun Chul Hong, Maria Teresa Landi, Philip Lazarus, Joshua Muscat, John McLaughlin, Ann G. Schwartz, Hongbing Shen, Isabelle Stucker, Kazuo Tajima, Keitaro Matsuo, Michael Thun, Ping Yang, John Wiencke, Angeline S. Andrew, Stephanie Monnier, Paolo Boffetta, Paul Brennan

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.

Original languageEnglish (US)
Pages (from-to)3081-3089
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Issue number11
StatePublished - Nov 2008

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'International lung cancer consortium: Pooled analysis of sequence variants in DNA repair and cell cycle pathways'. Together they form a unique fingerprint.

Cite this